Familial glucocorticoid resistance: an overview.

M Karl, G P Chrousos
{"title":"Familial glucocorticoid resistance: an overview.","authors":"M Karl, G P Chrousos","doi":"10.1055/s-0029-1211204","DOIUrl":null,"url":null,"abstract":"Familial glucocorticoid resistance is an inherited form of generalized end-organ insensitivity to glucocorticoids, associated with qualitative and/or quantitative abnormalities of the glucocorticoid receptor. The glucocorticoid resistance syndrome is characterized by elevated plasma corticotropin (ACTH) and cortisol concentrations, set at higher levels but maintaining a circadian rhythm, and no clinical evidence of hypoor hypercortisolism. The clinical spectrum of this syndrome is broad, ranging from completely asymptomatic to mildly or severely symptomatic, characterized by manifestations of mineralocorticoid and/or androgen excess (Chrousos et al., 1982; Lamberts et al., 1986). The secretion of glucocorticoids is strictly regulated by an elaborate feedback system, the suprahypothalamic-hypothalamic-pituitary-adrenal-axis (SHPA) (Kellerwood and Dallman, 1984; Dallman et al., 1987; Jakobsen and Sapolsky, 1991): Corticotropin releasing hormone (CRH) and arginine vasopressin (AVP), secreted by the hypothalamus, stimulate the release of ACTH by the pituitary gland. ACTH then stimulates secretion of glucocorticoids by the adrenal cortex. Glucocorticoids exert negative feedback effects on the hippocampus, the hypothalamus and the pituitary, presumably via the classic (Type II) glucocorticoid receptor and/or the mineralocorticoid receptor (glucocorticoid receptor type I) (De Kloet, 1991). By Experimental and","PeriodicalId":12104,"journal":{"name":"Experimental and clinical endocrinology","volume":"101 1","pages":"30-5"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0029-1211204","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0029-1211204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

Familial glucocorticoid resistance is an inherited form of generalized end-organ insensitivity to glucocorticoids, associated with qualitative and/or quantitative abnormalities of the glucocorticoid receptor. The glucocorticoid resistance syndrome is characterized by elevated plasma corticotropin (ACTH) and cortisol concentrations, set at higher levels but maintaining a circadian rhythm, and no clinical evidence of hypoor hypercortisolism. The clinical spectrum of this syndrome is broad, ranging from completely asymptomatic to mildly or severely symptomatic, characterized by manifestations of mineralocorticoid and/or androgen excess (Chrousos et al., 1982; Lamberts et al., 1986). The secretion of glucocorticoids is strictly regulated by an elaborate feedback system, the suprahypothalamic-hypothalamic-pituitary-adrenal-axis (SHPA) (Kellerwood and Dallman, 1984; Dallman et al., 1987; Jakobsen and Sapolsky, 1991): Corticotropin releasing hormone (CRH) and arginine vasopressin (AVP), secreted by the hypothalamus, stimulate the release of ACTH by the pituitary gland. ACTH then stimulates secretion of glucocorticoids by the adrenal cortex. Glucocorticoids exert negative feedback effects on the hippocampus, the hypothalamus and the pituitary, presumably via the classic (Type II) glucocorticoid receptor and/or the mineralocorticoid receptor (glucocorticoid receptor type I) (De Kloet, 1991). By Experimental and
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
家族性糖皮质激素抵抗:综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
In vivo-effect of intraadrenal nicotine and substance P application on rat adrenal medullary catecholamine secretion. Intracellular sex hormone-binding globulin (SHBG) in normal and neoplastic breast tissue--an additional marker for hormone dependency? Immune intervention in type I diabetes mellitus--current clinical and experimental approaches. Growth hormone therapy in adults: rationales, results, and perspectives. Endocrine characterization of the new dopamine autoreceptor agonist roxindole.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1